PT-141 / Bremelanotide in the United States
VYLEESI is an FDA-approved bremelanotide prescription product under NDA 210557 with a 1.75 mg autoinjector presentation and product-specific label. The 10 mg PT-141 research listings tracked here are not VYLEESI and do not inherit its approval or regulated supply chain.
- Evidence lane
- Research price board
- Global identity
- US research-market identity with a separate FDA-approved medicine record